Mangoceuticals, Inc.
MGRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -49.9% | 53.8% | 3.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.4% | 53.5% | 56.8% | 76.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $5 | $3 | $2 |
| SG&A Expenses | $0 | $5 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $7 | $0 | $1 | -$0 |
| Operating Expenses | $8 | $5 | $5 | $2 |
| Operating Income | -$8 | -$5 | -$5 | -$2 |
| % Margin | -8,953.5% | -3,134% | -4,440% | -1,594.3% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$8 | -$5 | -$5 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$5 | -$5 | -$2 |
| % Margin | -9,042.8% | -3,221.6% | -4,427.4% | -1,850.9% |
| EPS | -0.69 | -0.54 | -1.054 | -0.6 |
| % Growth | -27.8% | 48.7% | -75.5% | – |
| EPS Diluted | -0.69 | -0.54 | -1.054 | -0.6 |
| Weighted Avg Shares Out | 12 | 10 | 5 | 3 |
| Weighted Avg Shares Out Dil | 12 | 10 | 5 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $1 | $0 | $1 |
| EBITDA | -$8 | -$5 | -$4 | -$2 |
| % Margin | -8,924% | -2,711.3% | -4,060.3% | -1,593.4% |